220696-58-2Relevant articles and documents
Structure-Based Design of Selective Noncovalent CDK12 Inhibitors
Johannes, Jeffrey W.,Denz, Christopher R.,Su, Nancy,Wu, Allan,Impastato, Anna C.,Mlynarski, Scott,Varnes, Jeffrey G.,Prince, D. Bryan,Cidado, Justin,Gao, Ning,Haddrick, Malcolm,Jones, Natalie H.,Li, Shaobin,Li, Xiuwei,Liu, Yang,Nguyen, Toan B.,O'Connell, Nichole,Rivers, Emma,Robbins, Daniel W.,Tomlinson, Ronald,Yao, Tieguang,Zhu, Xiahui,Ferguson, Andrew D.,Lamb, Michelle L.,Manchester, John I.,Guichard, Sylvie
supporting information, p. 231 - 235 (2018/02/06)
Cyclin-dependent kinase (CDK) 12 knockdown via siRNA decreases the transcription of DNA-damage-response genes and sensitizes BRCA wild-type cells to poly(ADP-ribose) polymerase (PARP) inhibition. To recapitulate this effect with a small molecule, we sought a potent, selective CDK12 inhibitor. Crystal structures and modeling informed hybridization between dinaciclib and SR-3029, resulting in lead compound 5 [(S)-2-(1-(6-(((6,7-difluoro-1H-benzo[d]imidazol-2-yl)methyl)amino)-9-ethyl-9H-purin-2-yl)piperidin-2-yl)ethan-1-ol]. Further structure-guided optimization delivered a series of selective CDK12 inhibitors, including compound 7 [(S)-2-(1-(6-(((6,7-difluoro-1H-benzo[d]imidazol-2-yl)methyl)amino)-9-isopropyl-9H-purin-2-yl)piperidin-2-yl)ethan-1-ol]. Profiling of this compound across CDK9, 7, 2, and 1 at high ATP concentration, single-point kinase panel screening against 352 targets at 0.1 μm, and proteomics via kinase affinity matrix technology demonstrated the selectivity. This series of compounds inhibits phosphorylation of Ser2 on the C-terminal repeat domain of RNA polymerase II, consistent with CDK12 inhibition. These selective compounds were also acutely toxic to OV90 as well as THP1 cells.
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells
Yenugonda, Venkata Mahidhar,Deb, Tushar B.,Grindrod, Scott C.,Dakshanamurthy, Sivanesan,Yang, Yonghong,Paige, Mikell,Brown, Milton L.
experimental part, p. 2714 - 2725 (2011/06/17)
Inhibitors of cyclin-dependent kinases (CDKs) are an emerging class of drugs for the treatment of cancers. CDK inhibitors are currently under evaluation in clinical trials as single agents and as sensitizers in combination with radiation therapy and chemotherapies. Drugs that target CDKs could have important inhibitory effects on cancer cell cycle progression, an extremely important mechanism in the control of cancer cell growth. Using rational drug design, we designed and synthesized fluorescent CDK inhibitors (VMY-1-101 and VMY-1-103) based on a purvalanol B scaffold. The new agents demonstrated more potent CDK inhibitory activity, enhanced induction of G2/M arrest and modest apoptosis as compared to purvalanol B. Intracellular imaging of the CDK inhibitor distribution was performed to reveal drug retention in the cytoplasm of treated breast cancer cells. In human breast cancer tissue, the compounds demonstrated increased binding as compared to the fluorophore. The new fluorescent CDK inhibitors showed undiminished activity in multidrug resistance (MDR) positive breast cancer cells, indicating that they are not a substrate for p-glycoprotein. Fluorescent CDK inhibitors offer potential as novel theranostic agents, combining therapeutic and diagnostic properties in the same molecule.
Selective amidation of 2,6-dihalogenopurines: Application to the synthesis of new 2,6,9-trisubstituted purines
Piguel, Sandrine,Legraverend, Michel
, p. 7026 - 7029 (2008/02/11)
(Chemical Equation Presented) We report herein the palladium(0)/Xantphos- catalyzed cross-coupling of various amides with 2,6-dihalogenopurines, with substituent-dependent regioselectivity. Furthermore, subjecting the same 2,6-dihalogenopurines to SN